∿actor Xa inhibitors have demonstrated a safety advantage compared with older anticoagulants, but the number of patients on these newerĭrugs who are admitted to the hospital with a major bleed is growing due to their widespread adoption. ∺ndexanet alfa represents a potential important advance to the field of anticoagulation for Factor Xa inhibitor patients who suffer a major bleedingĮvent or those requiring emergency surgery, said William Lis, chief executive officer of Portola. ∼linical Science: Special Reports session at the American Heart Association 2014 Scientific Sessions on Monday, November 17, 2014, at 8:28 a.m. Inc.s (NYSE: PFE) direct Factor Xa inhibitor Eliquis (apixaban).ĭetailed data will be presented as an oral presentation during the Top-line efficacy data from the first of two ANNEXA-A (Andexanet Alfa a Novel Antidote to theĪnticoagulant Effects of fXA Inhibitors Apixaban) studies demonstrated that an intravenous (IV) bolus of andexanet alfa immediately and significantly reversed the anticoagulation activity of Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Andexanet alfa was well tolerated with no serious adverse events reported. Met its primary and secondary endpoints with high statistical significance. Food and Drug Administration-designated breakthrough therapy, (October 1, 2014) Portola Pharmaceuticals (Nasdaq: PTLA) today announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis To Be Featured atĪmerican Heart Associations ∼linical Science: Special Reports Session on November 17 Portola Pharmaceuticals Announces Phase 3 ANNEXA-A Study ofĪndexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints with High Statistical Significance
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |